•
Jun 30, 2021
Zomedica Q2 2021 Earnings Report
Reported consolidated financial results for the second quarter of 2021.
Key Takeaways
Zomedica reported a net loss for the three months ended June 30, 2021 of approximately $4.7 million, or $.005 per share. Revenue for the three months ended June 30, 2021 was $15,693 and resulted from the sale of our TRUFORMA® products and associated warranties.
Net loss for the quarter was approximately $4.7 million, or $.005 per share.
Revenue for the quarter was $15,693, resulting from TRUFORMA® product and warranty sales.
Cost of revenue for the quarter was $35,876.
Implemented a Customer Appreciation Program to place TRUFORMA® Instruments in veterinary clinics.